Search academic texts

Information × Registration Number 0215U001052, 0113U000266 , R & D reports Title Develop new regimens of short-term intensive antituberculosis chemotherapy in patients with newly detected pulmonary tuberculosis popup.stage_title Head Feschenko Yuriy Ivanovich, Registration Date 14-01-2015 Organization SO "National institute of phthisiology and pulmonology named after F. G. Yanovsky NAMS of Ukraine" popup.description2 Object: 318 patients with newly diagnosed pulmonary tuberculosis . Aim: to increase the effectiveness of treatment and reduce the time antituberculosis chemotherapy in patients with newly diagnosed pulmonary tuberculosis using optimal intensive phase antituberculosis chemotherapy through the use of moxifloxacin against a background of different routes of administration of antimycobacterial drugs. Methods: clinical, laboratory, radiological, microbiological, biochemical. Developed technology treatment of patients with newly diagnosed pulmonary tuberculosis with the use of moxifloxacin instead of ethambutol in the intensive phase of TB chemotherapy increases the frequency of disappearance of clinical manifestations of the disease (23,4% cough, sputum 27,9% after 2 weeks of treatment), reduces the time for sputum conversion average to 4,5 weeks compared with standard treatment regimens – average 5,9 weeks, and also results in reduction of large residual changes in lungs by 36,9% and relapses - by 36,1% over the 5-year follow-up. Were established that parenteral administration of isoniazid, rifampicin and ethambutol sodium salt hydrochloride as part of standard therapy in 15,7% had reduced the number of patients with signs of intoxication in the first two weeks of treatment, which reduced reseive sputum conversion termination average to 1,6 months with comparation to their oral reseption – average 2,1 ± 0,1 months. Was determined that use of isoniazid and rifampicin addition by nebulizer and salmeterol and fluticasone propionate in the intensive phase standard chemotherapy results in increased of frequency of termination bacterosecretion on - 29,7% for the 1st month of treatment; reduce the large residual changes in lungs - by 28.1%, bronchial stenosis scar II-III. - 38.7%.. Sphere of application - phthisiology Product Description popup.authors Аврамчук О. В. Гречаник Л. І. Гульчук Н. М. Гуменюм М. І. Клименко М. Т. Кужко Михайло Михайлович Линник М. І. Процик Любомир миронович popup.nrat_date 2020-04-02 Close